The success of Nexavar in thyroid cancer (PFS 10.8 months vs 5.8 months for the placebo) is the lead item in Pharmaletter and is being heavily covered elsewhere. This in an ASCO session which, to this point, seems pretty light on major breakthroughs.
Vin, you are right about the small number of potential patients. However, this is now one of the lead stories--e.g. the Adam Feuerstein article "ASCO '13: Onyx's Nexavar Delays Growth of Thyroid Cancer" was one of the lead stories in Yahoo All News. Such publicity should once again intensify the talk about Onyx being a very attractive takeover candidate.